Safety and Efficacy of Drug Resveratrol in Healing of Maxillofacial Fractures

Safety and Efficacy of Resveratrol in Healing of Maxillofacial Fractures: A Randomized Control Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037437

Enrollment

Registered

2021-10-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S028- Fractures of other specified skulland facial bones

Interventions

Intervention1: group A-Tab Resveratrol 500mg BD: Open reduction and internal fixation with administration of Tab Resveratrol 500mg BD for 1 month Control Intervention1: group B-Placebo group.: Open re

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between the age of 20-60 years with maxillofacial fractures 2. ASA I or II

Exclusion criteria

Exclusion criteria: 1. Age 60 years 2. Pregnant or lactating females 3. Hypercalcemia, Pagetâ??s disease or any other bone disorder 4. Malignant tumours 5. Patients earlier having radiation treatment. 6. Patients on Vitamin D therapy or any other bone medications

Design outcomes

Primary

Measure	Time frame
To evaluate and compare the safety and efficacy of resveratrol on healing of maxillofacial fractures.Timepoint: Pre-operatively 1st week post-operatively 4th week post-operatively 8th week post-operatively 12th week post-operatively	—

Secondary

Measure	Time frame
Evaluation of Bite forceTimepoint: Pre-operatively 1st week postoperatively 4th week postoperatively 8th week postoperatively 12th week postoperatively	—

Countries

India

Contacts

Public ContactDR SHIVKUMAR CHOPANE

AIIMS Jodhpur

ankitamody@gmail.com08003996891

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026